42419-59-0

Basic information

• Product Name: 1-Morpholinocyclohexane-1-carbonitrile
• Synonyms: 1-Morpholinocyclohexane-1-carbonitrile;1-Morpholinocyclohexanecarbonitrile;1-(4-Morpholinyl)cyclohexanecarbonitrile, 96%;1-Morpholin-4-ylcyclohexanecarbonitrile;1-(1-Cyclohexyl)morpholine;1-morpholin-4-ylcyclohexane-1-carbonitrile;1-morpholino-1-cyclohexanecarbonitrile;AH-034/32856040
• CAS NO: 42419-59-0
• Molecular Formula: C₁₁H₁₈N₂O
• Molecular Weight: 194.28
• Mol File: 42419-59-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 320.8°Cat760mmHg
• Flash Point: 147.8°C
• Appearance: /
• Density: 1.07g/cm³
• Vapor Pressure: 0.00031mmHg at 25°C
• Refractive Index: 1.517
• CAS DataBase Reference: 1-Morpholinocyclohexane-1-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Morpholinocyclohexane-1-carbonitrile(42419-59-0)
• EPA Substance Registry System: 1-Morpholinocyclohexane-1-carbonitrile(42419-59-0)

Safety Data

• Hazardous Substances Data: 42419-59-0(Hazardous Substances Data)

Usage

Heterocyclic compound

Contains a morpholine ring and a carbonitrile group This means that MCC has a complex ring structure with different types of atoms, including nitrogen in both the morpholine ring and the carbonitrile group.

Anti-tumor properties

MCC exhibits the ability to inhibit tumor growth This makes it a potential candidate for cancer treatment.

Anti-angiogenic properties

MCC can prevent the formation of new blood vessels This may be useful in limiting the growth of tumors by cutting off their blood supply.

Pharmaceutical industry applications

MCC has potential uses in the development of new drugs Its unique properties make it a valuable compound for creating medications targeting various diseases.

Research for cardiovascular and inflammatory diseases

MCC is being studied for its potential use in treating these conditions This suggests that it may have properties beneficial for managing or alleviating symptoms related to these diseases.

Synthesis of bioactive compounds

MCC has been studied for its potential use in creating other biologically active substances This indicates that it can serve as a building block or intermediate in the production of other valuable compounds.

Versatile compound

MCC has various potential applications in medicine and chemical synthesis This highlights the wide range of possible uses for this compound across different fields.

InChI:InChI=1/C11H18N2O/c12-10-11(4-2-1-3-5-11)13-6-8-14-9-7-13/h1-9H2

Upstream product

• 110-91-8 morpholine 
• 108-94-1 cyclohexanone 
• 7677-24-9 trimethylsilyl cyanide 
• 30822-30-1 OC₄H₈NCC₅H₁₀⁽¹⁺⁾*ClO₄^(1-)=(OC₄H₈NCC₅H₁₀)ClO₄ 
• 477531-69-4 di(morpholino)cyanoborane 
• 670-80-4 4-cyclohexen-1-ylmorpholine 
• 143-33-9 sodium cyanide 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 

Downstream Products

• 1934-49-2 1-[1-phenylcyclohexyl]morpholine hydrochloride 
• 64269-03-0 (1-morpholinocyclohexyl)methanamine 
• 939766-50-4 C₁₉H₂₈N₂O₃ 
• 21602-66-4 TCM 

Relevant articles and documents

Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B)

KDM5B (also known as PLU-1 and JARID1B) is 2-oxoglutarate and Fe2+ dependent oxygenase that acts as a histone H3K4 demethylase, which is a key participant in inhibiting the expression of tumor suppressors as a drug target. Here, we present the discovery of pyrazole derivatives compound 5 by structure-based virtual screening and biochemical screening with IC50 of 9.320 μM against KDM5B, and its subsequent optimization to give 1-(4-methoxyphenyl)-N-(2-methyl-2-morpholinopropyl)-3-phenyl-1H-pyrazole-4-carboxamide (27 ab), a potent KDM5B inhibitor with IC50 of 0.0244 μM. In MKN45 cells, compound 27 ab can bind and stabilize KDM5B and induce the accumulation of H3K4me2/3, bona fide substrates of KDM5B, while keep the amount of H3K4me1, H3K9me2/3 and H3K27me2 without change. Further biological study also indicated that compound 27 ab is a potent cellular active KDM5B inhibitor that can inhibit MKN45 cell proliferation, wound healing and migration. In sum, our finding gives a novel structure for the discovery of KDM5B inhibitor and targeting KDM5B may be a new therapeutic strategy for gastric cancer treatment.

Pharmaceutical compositions (by machine translation)

[Problem] imidazole compound or its pharmacologically acceptable salt in the melanocortin receptor activity that operates as an active ingredient of a pharmaceutical composition comprising. "I" general formula [a]" Formula, the aryl group may be substituted A ring represents a; R1 Represents a hydrogen atom, or an alkyl group which may be substituted represented; R2 Represents a hydrogen atom, a halogen atom or represents a; R3 The alkyl group may be substituted " represented by the imidazole compound, its pharmacologically acceptable salt as an active ingredient in a pharmaceutical composition. [Drawing] no (by machine translation)

Heterogeneously catalysed Strecker-type reactions using supported Co(ii) catalysts: Microwave vs. conventional heating

A range of α-aminonitriles could be efficiently prepared from various aldehydes/ketones and primary or secondary amines using a highly active and stable Co(ii) complex supported on different mesoporous supports at both room temperature and low temperature microwave irradiation under solventless conditions. Catalysts were also highly reusable under the investigated reaction conditions and could be reused at least 10 times without loss of catalytic activity. The Royal Society of Chemistry.